Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/13/2024 | $6.00 → $1.00 | Buy → Hold | Stifel |
| 6/13/2024 | $10.00 → $1.00 | Buy → Hold | Canaccord Genuity |
| 6/13/2024 | Buy → Hold | Needham | |
| 6/13/2024 | Buy → Neutral | H.C. Wainwright | |
| 3/8/2023 | $13.00 → $6.00 | Neutral → Underperform | BofA Securities |
| 3/8/2022 | $17.00 → $20.00 | Neutral → Overweight | JP Morgan |
| 11/1/2021 | $33.00 | Buy | Canaccord Genuity |
| 8/24/2021 | $33.00 → $35.00 | Buy | HC Wainwright & Co. |
4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
4 - Cara Therapeutics, Inc. (0001346830) (Issuer)
STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Helen M. Boudreau to its Board of Directors. Ms. Boudreau has more than 30 years of operating experience in a variety of industries, including the biotechnology and pharmaceutical sectors, in addition to serving as a director on numerous public boards. "We are pleased to welcome Helen to the Cara board," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "We look forward to leveraging her
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company's Board of Directors. Mr. Posner is currently the president and CEO of Cara Therapeutics (NASDAQ:CARA), a commercial-stage biopharmaceutical company.
STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors. Dr. von Moltke currently serves as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc. "We are very pleased to welcome Lisa to our board of directors," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "Her extensive clinical development and pharmacology expertise will be of great value as we continue executing o
STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced that it has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and reviewing strategic alternatives. "We are committed to evaluating a range of strategic options to maximize value for our shareholders," said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. "As part of this effort, our Board of Directors has approved a streamlined operating plan focused on cost-containment and cash conservation." There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica (NP). Oral difelikefalin did not demonstrate a meaningful clinical benefit at
STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2024. "Our notalgia paresthetica (NP) pivotal clinical program is progressing ahead of schedule and we now expect to report topline efficacy and safety results from KOURAGE 1 Part A by the end of the second quarter of 2024," said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. "We believe the medical dermatology community's intere
SC 13D - Cara Therapeutics, Inc. (0001346830) (Subject)
SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)
SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)
Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity
10-Q - Cara Therapeutics, Inc. (0001346830) (Filer)
10-Q - Cara Therapeutics, Inc. (0001346830) (Filer)
8-K - Cara Therapeutics, Inc. (0001346830) (Filer)
GAINERS: Global Hemp Group (OTC:GBHPF) shares closed up 117.39% at $0.04 CordovaCann (OTC:LVRLF) shares closed up 19.90% at $0.06 SOL Glb Inv (OTC:SOLCF) shares closed up 19.40% at $0.06 1933 Industries (OTC:TGIFF) shares closed up 11.81% at $0.01 Global Compliance (OTC:FUAPF) shares closed up 10.37% at $0.00 CLS Holdings USA (OTC:CLSH) shares closed up 6.01% at $0.04 22nd Century Group (NASDAQ:XXII) shares closed up 4.77% at $0.72 EnWave (OTC:NWVCF) shares closed up 4.53% at $0.17 Psychemedics (NASDAQ:PMD) shares closed up 3.52% at $2.24 cbdMD (AMEX:YCBD) shares closed up 3.11% at $0.63 LOSERS: Green Growth Brands (OTC:GGBXF) shares closed down 99.00% at $1e-06 Leafbuyer Techs (OTC:LBUY)
GAINERS: Pharmadrug (OTC:LMLLF) shares closed up 85.78% at $0.01 Heritage Cannabis Holding (OTC:HERTF) shares closed up 66.67% at $0.001 Cann Gr (OTC:CNGGF) shares closed up 37.93% at $0.02 4Front Ventures (OTC:FFNTF) shares closed up 27.16% at $0.10 Elixinol Wellness (OTC:ELLXF) shares closed up 25.00% at $0.00 Kaya Holdings (OTC:KAYS) shares closed up 22.97% at $0.04 CNBX Pharmaceuticals (OTC:CNBX) shares closed up 17.19% at $0.01 Body and Mind (OTC:BMMJ) shares closed up 12.02% at $0.03 Cansortium (OTC:CNTMF) shares closed up 10.62% at $0.12 Cara Therapeutics (NASDAQ:CARA) shares closed up 10.45% at $0.37 Auxly Cannabis Group (OTC:CBWTF) shares closed up 8.56% at $0.03 Scotts Miracle Gro
GAINERS: Australis Capital (OTC:AUSAF) shares closed up 9900.00% at $0.01 Global Hemp Group (OTC:GBHPF) shares closed up 70.36% at $0.05 Maple Leaf Green World (OTC:MGWFF) shares closed up 68.48% at $0.05 CordovaCann (OTC:LVRLF) shares closed up 42.50% at $0.06 Target Group (OTC:CBDY) shares closed up 25.00% at $0.00 Blueberries Medical (OTC:BBRRF) shares closed up 19.09% at $0.01 CLS Holdings USA (OTC:CLSH) shares closed up 17.00% at $0.04 Zelira Therapeutics (OTC:ZLDAF) shares closed up 15.32% at $0.55 Leafbuyer Techs (OTC:LBUY) shares closed up 14.67% at $0.02 Canopy Gwth (NASDAQ:CGC) shares closed up 10.92% at $7.14 SOL Glb Inv (OTC:SOLCF) shares closed up 10.66% at $0.05 Cansortium (OT
Stifel downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $6.00 previously
Canaccord Genuity downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $10.00 previously
Needham downgraded Cara Therapeutics from Buy to Hold
–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operatio
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com. About Cara Therapeutics Cara Therapeutics is a commercial-stage biopharmaceutical co
– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce reduction of up to 50% – – Cara ended 2023 with approximately $101 million in cash; runway extended into 2026 – – Company to host conference call and webcast today at 8:30 a.m. EST – STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the